# MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

Study · id `cardio:ct-nct07632157` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07632157](<https://clinicaltrials.gov/study/NCT07632157>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07632157

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

## Technical summary

Registry record NCT07632157. Randomized; double masking; primary purpose treatment. Start 2026-11-10 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 196 participants (planned count; ClinicalTrials.gov record NCT07632157, source copy `cardio:ctgov-nct07632157-2026-11-12`, retrieved 2026-11-18)
- Started: 2026-11-10 (actual) (ClinicalTrials.gov record NCT07632157, source copy `cardio:ctgov-nct07632157-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07632157, source copy `cardio:ctgov-nct07632157-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07632157, source copy `cardio:ctgov-nct07632157-2026-11-12`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07632157, source copy `cardio:ctgov-nct07632157-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07632157-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
- Acronym: MAGNETIC-AF
- Condition: Atrial Flutter With Rapid Ventricular Response
- Intervention (Drug): Magnesium Sulfate 2g
- Intervention (Drug): Magnesium Sulfate 4g
- Intervention (Drug): Saline (0.9% NaCl)
- Lead sponsor: Wake Forest University Health Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial flutter (`cardio:atrial-flutter`)
- Registry lists this organization as the lead sponsor: Wake Forest University Health Sciences (`cardio:wake-forest-health-sciences`)

## Provenance

Content hash: d5b5336d1ade84172fb47abea628f26a32455501eb35b8bc0708bfcdee06933a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
